Fierce Life Sciences Events’ Post

In my conversation with Fraiser Kansteiner and Fierce Pharma at #FierceJPMWeek I plan to share more information about strategic decisions made in my first year as CEO of Vir Biotechnology, Inc., including expanding our focus and harnessing the power of our proven antibody platform into additional areas including viral-associated and immune-mediated diseases. With the progress already made in our #HDV and #HBV clinical programs, we are well positioned to leverage Vir’s in-house immunology and virology expertise to help transform the lives of millions of patients worldwide. #Patientsarewaiting

this survey allows biotechs to show pharma companies what really matters to them when it comes to partnering

Which biotech/pharma players had the biggest fundraises this past July & August? Here we're covering the 20 biggest company fundraises during the peak of summer, put together by TLDR Biotech. For a larger list of 71 biotech/pharma fundraises over this time period, comment below or send me a DM. (And if you're interested in getting market research like this, happy to chat further.) —————————— Get the top biotech and pharma industry news, straight to your inbox and all in one email - that's TLDR Biotech. 🧬🔔 #biotech #pharma #pharmanews #biotechnews #tldrbiotech 

Who's new in the biotech and pharma space? Here we're covering 23 new company launches since May 2024, put together by TLDR Biotech. For a larger list of 35 biotech/pharma newco launches since beginning of May 2024, comment below or send me a DM. (And if you're interested in getting market research like this, happy to chat further.) —————————— Get the top biotech and pharma industry news, straight to your inbox and all in one email - that's TLDR Biotech. 🧬🔔 #biotech #pharma #pharmanews #biotechnews #tldrbiotech

I’ve seen many lists of biotech companies set up like this talking about various aspects of the companies. The disease areas that they are targeting, the technologies that they are using, or just new companies on the scene… but for the first time I get to see Kano Therapeutics on the list! Exciting!

📢 Attention, time change! May 16th, at 14:40, Stage 5    ✅ "From risk to remedy – Polish biotech's answers to sustain stable drug and diagnostics supply during shortages"  🎤 Join the discussion panel at Impact CEE, where Konstantin Matentzoglu (Polpharma Biologics) alongside Katarzyna Rolle (Polish Academy of Sciences), Dariusz Adamusiński (MedTech Poland), and moderator Joanna Bekker (Polityka Insight) will discuss how collaboration between businesses and science can strengthen supply chains when needed. Don't miss this important discussion! #IMPACTCEE #Innovation #Biotechnology #PolpharmaBiologics

Novelty for those of us pursuing new therapeutic agents within the specialized drug discovery domain extends far beyond what is merely new. It demands both innovation and practical applicability. Here's our take on the challenge of novelty in drug discovery. #drugdiscovery #biopharma #drugresearch #innovation #seeIPdifferently #biotech #drugresearch https://lnkd.in/etXdjbtZ

Check out the latest episode of The BioCentury Show with new BIO (Biotechnology Innovation Organization) President & CEO John F. Crowley. ✅ Watch: https://lnkd.in/d-Fr_KRD John speaks with my BioCentury Inc. colleague Steve Usdin about several topics, including: ➢ Why BIO's position on the #Biosecure Act and WuXi AppTec and WuXi Biologics has changed. ➢ Why FDA should create a rare diseases center of excellence. ➢ Why BIO is planning "fly out" visits to cities around the U.S. ➢ Where common ground can be found between the biotech industry and Capitol Hill. ➢ How BIO plans to demonstrate the unintended consequences of the #IRA on drug development. And much more.... Watch or listen on YouTube. #biotech #biopharma #drugdevelopment #drugpricing #decoupling

Not being the tallest myself, I've always held a special place in my heart for the beauty of small things. This might be why Fragment-Based Drug Discovery (FBDD 😍 ) resonates so strongly with me! I'm thrilled to share that Selvita's Project Owner, Aleksandra Bebel, will be participating in the upcoming 9thRSC-BMCS (https://bit.ly/49NNavX). Selvita has a number of exciting FBDD projects where Aleksandra played a key role in X-ray screening of fragments, with my skilled team supporting them with CADD. Our main tools for this work are InfiniSee and SeeSAR (thanks Marcus Gastreich, BioSolveIT), and we're also grateful for the strong support from Selvita's AI Team (kudos to Joerg Wichard and his Team). Whether you're already passionate about FBDD or just curious to learn more, I highly recommend attending the event and connecting with Aleksandra Bebel for a deeper dive into this fascinating field! #drugdiscovery #pharma #biotech #fragmentbased #medicinalchemistry #structuralbiology

There’s still time to participate in this year’s biotech survey. Share your thoughts and help shape the future of biopharma partnering! By completing this survey, we’ll send you a guide of 24 top tips to help you prepare for and navigate BIO International Convention, the largest annual partnering event. Find the survey here: https://lnkd.in/es-UT-6K #biopharma #biopharmapartnering #biotech